Daniel H. Albert
100 Abbott Park Road
R4N2/W-1
Abbott Park
IL 60064-3500
Name/email consistency: high
- Preclinical Characterization of ABT-348, a Kinase Inhibitor Targeting the Aurora, Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor, and Src Kinase Families. Glaser, K.B., Li, J., Marcotte, P.A., Magoc, T.J., Guo, J., Reuter, D.R., Tapang, P., Wei, R.Q., Pease, L.J., Bui, M.H., Chen, Z., Frey, R.R., Johnson, E.F., Osterling, D.J., Olson, A.M., Bouska, J.J., Luo, Y., Curtin, M.L., Donawho, C.K., Michaelides, M.R., Tse, C., Davidsen, S.K., Albert, D.H. J. Pharmacol. Exp. Ther. (2012)
- Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Albert, D.H., Tapang, P., Magoc, T.J., Pease, L.J., Reuter, D.R., Wei, R.Q., Li, J., Guo, J., Bousquet, P.F., Ghoreishi-Haack, N.S., Wang, B., Bukofzer, G.T., Wang, Y.C., Stavropoulos, J.A., Hartandi, K., Niquette, A.L., Soni, N., Johnson, E.F., McCall, J.O., Bouska, J.J., Luo, Y., Donawho, C.K., Dai, Y., Marcotte, P.A., Glaser, K.B., Michaelides, M.R., Davidsen, S.K. Mol. Cancer Ther. (2006)
